Introduction
Hypertension is a major risk factor for cardiovascular morbidity and mortality. Hypertension shows a significant degree of heritability and is commonly recognized as a complex, polygenic disorder, with the exception of rare monogenic forms. The nature of this complex disease makes it difin spontaneously hypertensive rats (SHR), perhaps through elevated sympathetic outflow (1, 2) . Recently, Ito et al. demonstrated that injection of the excitatory amino acid (EAA) antagonist kynurenic acid (KYN) into the rostral ventrolateral medulla (RVLM) of SHR reduced mean arterial pressure by 40 mmHg, whereas similar injection in WistarKyoto rats (WKY) had no significant effects on blood pressure (3) . Based on this observation, it has been hypothesized that there is a relative increase in the EAA-mediated drive of RVLM vasomotor neurons in SHR.
The brain contains several tryptophan metabolites that affect neuronal function. Kynurenines originate from tryptophan through the rate-limiting-step enzyme indoleamine-2,3-dioxygenase. KYN is synthesized from kynurenine by kynurenine aminotransferase (4) , and is a potent N-methyl-D-aspartate antagonist (5) . Kynurenine is a substrate of several enzymes and, in particular, may be metabolized into anthranilic acid and 3-hydroxy-kynurenine by the action of the enzymes kynureninase and kynurenine hydroxylase, respectively (Fig. 1) . In the present study, we investigated the hypothesis that a relative increase in the EAA-mediated drive of RVLM vasomotor neurons in SHR, and as well as the resulting higher blood pressure in SHR, may be due to derangement of one of the enzymes that affects the KYN level in the brain. We performed F2 analyses using genetic polymorphisms of the kynureninase gene (KYNU) (6), kynurenine hydroxylase gene, and kynurenine aminotransferase type I and II genes. Only the polymorphisms of KYNU influenced blood pressure in the F2 population. Thus, we studied KYNU in the present study.
Materials and Methods

Experimental Animals and Genetic Crosses
The F2 rats used in the present study were obtained, and SBP, DBP, and heart rate were measured directly, as described previously (7, 8) . Briefly, male SHR/Hos rats were mated with female WKY/Hos rats (Sankyo Co., Ltd., Shizuoka, Japan) to produce F1 rats, and male F1 and female F1 rats were then intercrossed to produce an population consisting of 105 male rats. At 15 weeks of age, a catheter was implanted into the abdominal aorta via a femoral artery. All procedures on animals were conducted in accordance with institutional guidelines.
Sequencing
Reverse-transcription polymerase chain reaction (RT-PCR) products corresponding to the entire coding sequence of WKY-and SHR-KYNU mRNA were produced. After the PCR products were purified using a QIAquick-spin PCR Purification Kit (Quiagen, Hilden, Germany), they were sequenced by cycle-sequencing in the presence of Big Dye terminators followed by sequence analysis on an ABI Prism 3100 DNA sequencer (Perkin Elmer, Norwalk, USA). Genetic variations between SHR and WKY were screened by sequencing KYNU, and a genetic variation in intron 11 was used for F2 segregation analysis using the following primers. The genotype of the F2 rats was determined by sequencing.
Sense : 5 -gatggttcggccatgaactc-3 . Antisense : 5 -tccgccatggtaatgtttga -3 .
Chromosomal Assignment and Quantitative Trait Loci (QTL) Analysis
Since the human KYNU (2p23.3-q14.3) is homologous to a chromosomal region on rat chromosome 3, we genotyped the microsatellite markers on chromosome 3 to elucidate the KYNU locus. Genotyping was performed through PCR amplification of DNA around the polymorphic microsatellite markers from the total genomic DNA of the WKY SHR cross using the appropriate PCR primer pairs (custom-made by Amersham Pharmacia Biotechnology, Buckinghamshire, UK), based on information from Research Genetics. The associations between KYNU genotype and phenotypic variables, including body weight, heart rate, SBP, DBP, residuals of SBP, and residuals of DBP, were assessed by ANO VA. In addition, multiple linear regression analysis was performed with other covariates. Map Manager QT (9) was used for QTL analysis at the KYNU locus. Since multiple regression analysis indicated that SBP and DBP were influenced by heart rate and body weight, residuals of SBP and DBP were calculated by adjusting for both these variables. RSBP and RDBP were subjected to QTL analysis.
Assessment of the Expression Level of KYNU
The mRNA expression level of KYNU was assessed by a competitive RT-PCR method (10) , in which deletion-mutated cRNA was included as an internal standard. Rat KYNU cDNA was amplified using a rat kidney cDNA mixture with the following primers. Sense: 5 -gccatgaggtagggaaacgtccttgg-3 (353 -378, U68168). Antisense: 5 -gaacaggaccacagcaattgagtctcc-3 (711 -685, U68168). The resultant cDNA was subcloned into pCR4-TOPO (Invitrogen, Carlsbad, USA). The resultant plasmid was digested with Xba I (529) and Bsm I (454), blunt-ended with klenow treatment, and self-ligated. The resultant plasmid was digested with Not I, and the cRNA was synthesized by T7 RNA polymerase. The plasmid DNA was digested with DNase I. The resultant cRNA lacks a region between nucleotides 454 and 529 (U68168).
RNA was extracted according to the method of Chomczynski and Sacchi (11) from the brainstem of SHR/Hos and WKY/Hos. Total RNA (2 µg) combined with (10 7 ng) deletion-mutated cRNA was reverse-transcribed, and the resultant cDNA mixture was amplified by the primers listed above. The length of the PCR product from native KYNU mRNA was 352 bp, and that from the deletion-mutated cRNA was 284-bp. The expression level of the mRNA was expressed as the ratio of the 352-bp PCR fragment to the 284-bp PCR fragment.
Results
Sequence Analysis
Sequence analysis of KYNU cDNA revealed an A/G substitution in the SHR strain at position 1291, within exon 16. As a result, isoleucine in WKY is replaced by valine in SHR. We also found a G/A substitution in the SHR strain in intron 11, which was in complete disequilibrium with A1291G and was used for genotyping in F2 rats.
KYNU Locus and QTL Analysis
The distribution of body weight (A), heart rate (B), SBP (C), DBP (D), RSBP (E), and RDBP (F) in F2 progeny classified according to the genotype of KYNU is shown in Fig. 2 . KYNU genotype had no significant effect on body weight or heart rate. On the other hand, KYNU genotype did influence SBP ( p 0.0197, ANOVA) and DBP ( p 0.0962, ANOVA). Multiple regression analyses strengthened the importance of the KYNU locus in blood pressure regulation. Multiple regression analysis in which body weight, heart rate and the genotype of KYNU (WW SW 1, SS 2) indicated that body weight ( p 0.0261), heart rate ( p 0.0005), and the genotype of KYNU (WW SW 1, SS 2) ( p 0.0011) affected SBP. A similar multiple regression analysis indicated that DBP was also affected by these three variables (body weight, p 0.0081; heart rate, p 0.0163; the genotype of KYNU (WW SW 1, SS 2), p 0.0375).
Since SBP and DBP were influenced by body weight and heart rate, residuals of SBP and DBP were calculated by adjusting for these two phenotypic variables. Residuals represented the difference between the actual blood pressure value and the value predicted from body weight and heart rate. RSBP and RDBP were subjected to the following QTL analysis.
The LOD score plots at the KYNU locus are shown in Fig.  3 . The KYNU locus was associated with SBP and RSBP, with LOD scores of 2.0 and 3.3, respectively. KYNU itself turned out to be the gene most likely to affect SBP and RSBP. Furthermore, this association with blood pressure decreased in proportion to the distance from KYNU.
Assessment of the Expression Level of KYNU
Since KYNU is a candidate gene for hypertension in SHR based on the above analyses, we assessed the expression level of KYNU in the brainstem of SHR and WKY. The expression levels of KYNU in the brainstem were too low to detect by conventional Northern blot analysis, so we used a competitive RT-PCR method. As shown in Fig. 4 , the expression level of KYNU mRNA in the brainstem was about 5.1 and 2.9 times higher in 4-week-old and 10-week-old SHR than in age-matched WKY, respectively.
Discussion
The SHR is the most widely used animal model of human essential hypertension (12, 13) . In this strain, the sympathetic neurons have been shown to exhibit hyperfunction and hyperinnervation of peripheral target organs (1, 2) . The RVLM plays a critical role in the tonic and reflexive regulation of arterial blood pressure. The ongoing activity of RVLMspinal neurons is responsible for the generation of baseline sympathetic vasomotortone, and acute inhibition of this region causes a marked decrease in arterial blood pressure (3, 14 -16) , similar to that seen in response to cervical spinal cord transection or inhibition of the autonomic nervous system (17) . Ito 
Fig. 2. Phenotypes of F2 rats according to the kynureininase genotype. (A) Body weight, (B) heart rate, (C) systolic blood pressure (SBP), (D) diastolic blood pressure (DBP), (E) residuals of SBP (RSBP), (F) residuals of DBP (RDBP). WW, rats homozygous for WKY/Hos allele (n 29); WS, heterozygous rats (n 57); SS, rats homozygous for SHR/Hos allele (n 19). The mean value is indicated by the horizontal line.
genetically hypertensive rats (14) . We hypothesized that a relative increase in the EAA-mediated drive of RVLM vasomotor neurons in SHR may be due to derangement of one of the enzymes that affects the KYN level in the brain. The present study indicated that increased expression of KYNU might contribute to hypertension in SHR.
Moroni et al. have shown that inhibition of kynureninase, as achieved by the intraperitoneal administration of m-nitrobenzoylalanine, results in a large accumulation of KYN in the brain (18) . This observation indicates that the KYN level is affected by the kynureninase level. In the present study, we confirmed that there is a difference in the expression of KYNU mRNA in the brainstem between SHR and WKY rats. The increased expression of KYNU in the SHR brainstem may decrease the KYN level. The lower KYN level may cause hypertension in SHR, since the injection of KYN into the brainstem of SHR decreases blood pressure as much as 40 mmHg (3) . The association of the SS genotype of KYNU with higher blood pressure strongly supports the notion that KYNU contributes to hypertension in SHR.
Recently, the availability of a rat genetic linkage map has made it possible to more accurately define those boundaries of QTL that influence blood pressure, which have been mapped to varying degrees of precision on rat chromosomes 1, 2, 3, 4, 5, 10, 17, 18, 19, and X (8,19 -26) . The rat KYNU locus was located between D3Rat53 and D3Rat80. Clark et al. reported a sex-specific BP QTL on rat chromosome 3 in male stroke-prone SHR (SHRSP) WKY crosses in the region of the anonymous marker D3Mgh16 (19) . Nara et al. found a significant linkage of D3Mgh16 with basal SBP in male and female SHRSP WKY/izm crosses (20) . However, the locus of the marker for D3Mgh16 was 16 cM from KYNU, and they did not examine the KYNU locus. The genes for uncharacterized bone marrow protein BM046, PRO0159 protein, and hypothetical protein FLJ11753 are reportedly near the human KYNU. Although the relevance of these genes to blood pressure regulation is unclear, further study may be necessary to exclude these genes from among the candidate genes for hypertension in SHR.
Fig. 3. QTL plot of chromosome 3 near the kynureninase locus. (A) Systolic blood pressure (SBP), (B) diastolic blood pressure (DBP), (C) residuals of SBP (RSBP), (D) residuals of DBP (RDBP). Distances between markers are map units in cM.
In the present study, the peaks of the most significant QTL in terms of SBP and RSBP on chromosome 3 (LOD 2.0 and 3.3) were close to the KYNU locus, and this positive association with blood pressure decreased in proportion to the distance from KYNU. Although it will be necessary to make transgenic animals with KYNU before reaching any definitive conclusions, the present study strongly suggests that KYNU is one of the genes contributing to hypertension in SHR.
